The evolving role of catumaxomab in gastric cancer

@article{Lordick2008TheER,
  title={The evolving role of catumaxomab in gastric cancer},
  author={Florian Lordick and Katja Ott and J{\"u}rgen Weitz and Dirk J{\"a}ger},
  journal={Expert Opinion on Biological Therapy},
  year={2008},
  volume={8},
  pages={1407 - 1415}
}
Background: Gastric cancer is a condition with a high medical need. Even after R0 resection the rate of peritoneal and other distant site recurrences is high. Novel therapeutic approaches include trifunctional antibodies (trAb) that recruit and activate different types of immune effector cells at the tumour site. The trAb catumaxomab has dual antigen specificity for epithelial cell adhesion molecule and CD3 and binds to Fcγ-receptor-positive accessory cells. Intraperitoneal administration of… 

Efficacy of catumaxomab in tumor spheroid killing is mediated by its trifunctional mode of action

TLDR
A strong dose-dependent antitumor response mediated by catumaxomab is found, with volume-decreased or completely destroyed tumor spheroids together with a massive immune cell infiltration and decreased signals for cancer cell viability and clonogenicity.

Advanced gastric cancer--slow but steady progress.

Is Preoperative Chemotherapy Followed by Surgery the Appropriate Treatment for Signet Ring Cell Containing Adenocarcinomas of the Esophagogastric Junction and Stomach?

TLDR
Although response to neoadjuvant chemotherapy is rare in SRC, it is associated with improved outcome, and chemotherapy might not generally be abandoned in S RC, so a stratification based on SRC should be included in clinical trials.

Full Length Research Article IMPROVING SURVIVAL IN ADVANCED GASTRIC CANCER: A QUALITATIVE APPROACH

TLDR
The analysis revealed chemotherapy followed by surgery to be the preferred protocol for treatment of gastric cancer(primary optio n), the exact selection of the agents and surgery involved being debatable.

Targeted biopharmaceuticals for cancer treatment.

Prinzipien der neoadjuvanten Therapie

TLDR
How the basic principles of neoadjuvant therapy translate into clinical practice is summarized and a review of current developmental perspectives in this field is given.

Magen- und Adenokarzinome des ösophagogastralen Übergangs

TLDR
Neoadjuvant therapy seeks to achieve downsizing of the primary tumor, lowering of the T and N categories and eradication of micrometastases and survival can be improved by neoadjuant chemotherapy.

Neoadjuvante und adjuvante Therapie des Magen- und Ösophaguskarzinoms

TLDR
It is shown that multimodal treatment can lead to better outcomes than surgery alone, and patients with locally advanced gastric and oesophageal cancers should always be referred to an experienced high-volume centre where findings are discussed by a multidisciplinary tumour board.

Multimodale Therapie bei Karzinomen des gastroösophagealen Übergangs (GÖÜ)

TLDR
It has been shown that multimodal treatment can improve the outcome in comparison to surgery alone and Adenothat perioperative chemotherapy significantly improves the survival of patients with adenocarcinoma of the stomach and the gastroesophageal cancers.

References

SHOWING 1-10 OF 79 REFERENCES

Efficacy of intraperitoneal treatment with the trifunctional antibody catumaxomab in patients with GI-tract cancer and peritoneal carcinomatosis: A matched-pair analysis.

TLDR
Intraperitoneal treatment with the trifunctional antibody catumaxomab may be an attractive option for treatment of patients with peritoneal carcinomatosis due to GI-tract cancer and convincing results have to be further investigated in clinical phase II/III trials.

Intraoperative, adjuvant treatment of gastric cancer with the trifunctional antibody catumaxomab compared to surgery alone: A phase II study

TLDR
This data indicates that the trifunctional antibody catumaxomab (anti-EpCAM × anti-CD) combination may be a viable treatment option for gastric cancer patients with a high risk of peritoneal recurrence after surgery.

Intraoperative Immuntherapie mit dem trifunktionalen Antikörper Catumaxomab bei Patienten mit fortgeschrittenem Magen-, Colon- und Pankreaskarzinom: Ergebnisse einer Phase I Pilotstudie

TLDR
Intraoperative immunotherapy with trifunctional antibodies is technically feasible and safe up to 20 µg even in patients with extended tumor surgery, which offers promising opportunities to prevent tumor recurrence and peritoneal carcinomatosis in GI-tract cancer.

Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM × anti-CD3): a phase I study

TLDR
Five micrograms of catumaxomab with a pre-medication of 40 mg dexamethasone and antihistamines can be recommended as first dose for i.v. therapy consisting of multiple catumxomab infusions for patients with NSCLC.

Treatment of ovarian cancer patients with malignant ascites using the trifunctional antibody catumaxomab: Results of a phase II/III study

TLDR
Catumaxomab (anti-EpCAM × anti-CD3) is known to effectively treat ovarian carcinoma patients with atypical prognosis and reduced quality of life with prior treatment with EMT.

Recent advances in multimodal treatment for gastric cancer: a review

TLDR
A more distinct definition of prognostic and predictive markers is warranted in view of the side effects of pre- and foremost postoperative therapies, and it remains uncertain which subgroups of patients should routinely undergo multimodal treatment.

Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM × Anti-CD3 Antibody: A Phase I/II Study

TLDR
It is suggested that catumaxomab is a promising treatment option in ovarian cancer patients with malignant ascites because it prevented the accumulation of ascites and efficiently eliminated tumor cells with an acceptable safety profile.

[Prognostic factors for development of peritoneal carcinosis in stomach carcinoma].

TLDR
A clinical correlation was found between the occurrence of peritoneal dissemination and tumour stage pT3, pN2, G3, cancer of the whole stomach and cancer at the anastomotic site after partial gastric resection.

Advanced gastric cancer with or without peritoneal carcinomatosis treated with hyperthermic intraperitoneal chemotherapy: a single western center experience.

  • S. ScaringiR. Kianmanesh S. Msika
  • Medicine
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • 2008

Current status and future of chemotherapy and biochemotherapy in gastroesophageal cancers.

TLDR
Improvements in outcome may be achieved when even more active chemotherapy combinations including docetaxel are systematically implemented into the preoperative treatment of locally advanced gastroesophageal cancers.
...